In the last trading session, 2.81 million shares of the Moleculin Biotech Inc (NASDAQ:MBRX) were traded, and its beta was 2.18. Most recently the company’s share price was $1.15, and it changed around $0.09 or 8.49% from the last close, which brings the market valuation of the company to $16.10M. MBRX currently trades at a discount to its 52-week high of $6.23, offering almost -441.74% off that amount. The share price’s 52-week low was $0.40, which indicates that the current value has risen by an impressive 65.22% since then. We note from Moleculin Biotech Inc’s average daily trading volume that its 10-day average is 0.78 million shares, with the 3-month average coming to 5.82 million.
Moleculin Biotech Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended MBRX as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Moleculin Biotech Inc is expected to report earnings per share of 0 for the current quarter.
Moleculin Biotech Inc (NASDAQ:MBRX) trade information
Instantly MBRX has showed a green trend with a performance of 8.49% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.3200 on recent trading dayincreased the stock’s daily price by 12.88%. The company’s shares are currently down -32.35% year-to-date, but still up 5.50% over the last five days. On the other hand, Moleculin Biotech Inc (NASDAQ:MBRX) is 7.48% up in the 30-day period. We can see from the shorts that 1.08 million shares have been sold at a short interest cover period of 0.08 day(s).
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 26.36%. Moleculin Biotech Inc earnings are expected to increase by 73.47% in 2025, but the outlook is positive 37.81% per year for the next five years.
MBRX Dividends
Moleculin Biotech Inc’s next quarterly earnings report is expected to be released on 2025-Mar-20.
Moleculin Biotech Inc (NASDAQ:MBRX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.75% of Moleculin Biotech Inc shares, and 3.49% of them are in the hands of institutional investors. The stock currently has a share float of 3.52%.
Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 30.31 shares worth $34861.0, making up 0.23% of all outstanding shares. On the other hand, Fidelity Extended Market Index Fund held roughly 14.58 shares worth around $16762.0, which represents about 0.11% of the total shares outstanding.
